Pharsight

1. List of Vagifem drug patents

Application	Filing Date	Opposition Party	Legal Status
EP01270333A	2012-08-08	Helm AG	Revoked
EP01270333A	2012-08-01	Laboratorios Léon Farma, S.A.	Revoked

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7018992	NOVO NORDISK INC	Hormone composition	Sep, 2022 (8 months ago)

Do you want to check out VAGIFEM patents from before 2022?

Drugs and Companies using ESTRADIOL ingredient

Market Authorisation Date: 26 March, 1999

Treatment: Treatment of atrophic vaginitis due to menopause

Dosage: TABLET;VAGINAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
10 mcg	02 Jan, 2013	1	29 May, 2015	17 Sep, 2022	Eligible

Strength	Dosage	Availability
10MCG	TABLET;VAGINAL	Prescription
25MCG	TABLET;VAGINAL	Discontinued

VAGIFEM family patents

Denmark

United States

European Union

Germany

Spain

Japan

Cyprus

Australia

Portugal

Austria

2. List of Victoza drug patents

Application	Filing Date	Opposition Party	Legal Status
EP17710160A	2022-05-04	STADA Arzneimittel AG	Granted and Under Opposition
EP17710160A	2022-05-04	Dr. Schön, Neymeyr & Partner Patentanwälte mbB	Granted and Under Opposition
EP17710160A	2022-05-03	SANDOZ AG	Granted and Under Opposition
EP17710160A	2022-05-03	Adalvo Ltd.	Granted and Under Opposition
EP17710160A	2022-04-28	Teva Pharmaceutical Industries Ltd.	Granted and Under Opposition
EP17196501A	2019-12-06	Hoffmann Eitle	Granted and Under Opposition
EP17196501A	2019-12-06	Generics (U.K.) Limited	Granted and Under Opposition
EP17196501A	2019-12-05	Dr. Reddy's Laboratories Limited	Granted and Under Opposition
EP17196501A	2019-12-04	Galenicum Health S.L.U.	Granted and Under Opposition
EP17196501A	2019-12-04	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP04797453A	2018-08-22	Uexküll & Stolberg Partnerschaft von Patent- und Rechtsanwälten mbB	Opposition rejected
EP04797453A	2018-08-21	Wittkopp, Alexander	Opposition rejected
EP04797453A	2018-08-21	Teva Pharmaceutical Industries Ltd	Opposition rejected
EP04797453A	2018-08-21	Generics (U.K.) Limited	Opposition rejected
EP04797453A	2018-08-20	Sandoz AG	Opposition rejected
EP04797453A	2018-08-20	Fresenius Kabi Deutschland GmbH	Opposition rejected
EP08708028A	2011-07-06	Bock Wolfgang	Patent maintained as amended
EP06121820A	2010-05-18	SANOFI-AVENTIS DEUTSCHLAND GMBH	Opposition rejected
EP02745182A	2008-09-26	AMYLIN PHARMACEUTICALS, INC.	Opposition rejected

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
US8114833	March, 2022	Terminated-Settled	Novo Nordisk A/S	Fresenius Kabi USA, LLC
US8114833	July, 2020	Terminated-Settled	Novo Nordisk A/S	Pfizer Inc.
US8114833	December, 2019	Terminated-Settled	Novo Nordisk A/S	Pfizer Inc.
US9265893	January, 2014	Decision	Torben Stroem Hansen et al

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6268343	NOVO NORDISK INC	Derivatives of GLP-1 analogs	Aug, 2022 (9 months ago)
US8114833	NOVO NORDISK INC	Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices	Aug, 2025 (2 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8846618	NOVO NORDISK INC	Stable formulation of modified GLP-1	Jun, 2022 (11 months ago)
US8846618 (Pediatric)	NOVO NORDISK INC	Stable formulation of modified GLP-1	Dec, 2022 (5 months ago)
US6268343 (Pediatric)	NOVO NORDISK INC	Derivatives of GLP-1 analogs	Feb, 2023 (3 months ago)
US8579869	NOVO NORDISK INC	Needle mounting system and a method for mounting a needle assembly	Jun, 2023 (26 days from now)
US8579869 (Pediatric)	NOVO NORDISK INC	Needle mounting system and a method for mounting a needle assembly	Dec, 2023 (6 months from now)
US7762994	NOVO NORDISK INC	Needle mounting system and a method for mounting a needle assembly	May, 2024 (11 months from now)
US7762994 (Pediatric)	NOVO NORDISK INC	Needle mounting system and a method for mounting a needle assembly	Nov, 2024 (1 year, 5 months from now)
US8114833 (Pediatric)	NOVO NORDISK INC	Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices	Feb, 2026 (2 years from now)
US9265893	NOVO NORDISK INC	Injection button	Sep, 2032 (9 years from now)
US9265893 (Pediatric)	NOVO NORDISK INC	Injection button	Mar, 2033 (9 years from now)
US9968659	NOVO NORDISK INC	Liraglutide in cardiovascular conditions	Jan, 2037 (13 years from now)
US9968659 (Pediatric)	NOVO NORDISK INC	Liraglutide in cardiovascular conditions	Jul, 2037 (14 years from now)

Do you want to check out VICTOZA patents from before 2022?

Exclusivity	Exclusivity Expiration
New Patient Population (NPP)	Jun 17, 2022
Pediatric Exclusivity (PED)	Dec 17, 2022

Drugs and Companies using LIRAGLUTIDE RECOMBINANT ingredient

Market Authorisation Date: 25 January, 2010

Treatment: Method of reducing the risk of cardiovascular death, non-fatal myocardial infarction, and/or non-fatal stroke in adults with type 2 diabetes mellitus and established cardiovascular disease by administ...

Dosage: SOLUTION;SUBCUTANEOUS